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Background: Randomized controlled trials (RCTs) provide the highest level of evidence and are likely to influ-
ence clinical decision-making. This study evaluated the reporting quality of RCT abstracts on drug therapy of 
periodontal disease and assessed the associated factors.
Material and Methods: The Pubmed database was searched for periodontal RCTs published in Science Citation 
Indexed (SCI) dental journals from 2010/01/01 to 2019/07/17. Information was extracted from the abstracts ac-
cording to a modified Consolidated Standards of Reporting Trials (CONSORT) guideline checklist. The data 
was analyzed using descriptive statistical analysis and the statistical associations were examined using the linear 
regression analysis (P<0.05).
Results: This study retrieved 1715 articles and 249 of them were finally included. The average overall CONSORT 
score was 15.6 ± 3.4, which represented 40.9% (±0.6) of CONSORT criteria filling. The reporting rate of some 
items (trial design, numbers analyzed, confidence intervals, intention-to-treat analysis or per-protocol analysis, 
harms, registration) was less than 30%. The adequate reporting rate of some items (participants, randomization, 
numbers analyzed, confidence intervals, intention-to-treat analysis or per protocol analysis) was no more than 
4%. None of the abstracts reported funding. According to the multivariable linear regression results, number of 
authors (P=0.030), word count (P<0.001), continent (P=0.003), structured format (P<0.001), type of periodontal 
disease (P<0.001) and international collaboration (P=0.023) have a significant association with reporting quality.
Conclusions: The quality of RCT abstracts on drug therapy of periodontal disease in SCI dental journals remained 
suboptimal. More efforts should be made to improve RCT abstracts reporting quality.
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Introduction
Randomized controlled trials (RCTs) are magnificent 
in medical research and provide the highest level of 
evidence (1). For conducting good quality RCTs to ob-
tain the precise clinical outcomes, appropriate design 
and execution are essential. Readers often screen the 
title and abstract of a study to decide whether to re-
trieve the full text or not. So abstract is a very impor-
tant component of a study and is most readily available 
to all researchers and clinicians. Sometimes abstract 
may be the only information available to readers. This 
may be because of articles not for free, or download 
limitation for low Internet speed. Especially when ar-
ticles published in other languages, only abstracts are 
translated into the readers’ own language. Hence, the 
accuracy and reporting quality of abstracts are con-
sidered to be of particular importance. To improve 
the reporting quality of RCT abstracts, guidance on 
reporting RCT abstracts has been released by the Con-
solidated Standards of Reporting Trials (CONSORT) 
group in 2008 (2). The CONSORT guidelines have 
been included in the author’s guidelines in various 
dental journals, and authors are required to follow the 
CONSORT checklist (3).
The RCT abstracts guidelines direct authors on the right 
way to present the information and illuminate the key 
points that should be included. These guidelines also 
recommended the use of structured format in the RCT 
abstracts. It has been recently reported that the qual-
ity of RCT abstracts remains suboptimal (4). Further-
more, the quality of RCT abstracts in leading dentistry 
journals has been documented to be suboptimal (5). A 
number of RCTs may have been overlooked, in which 
these were carried out adequately, but reported poorly. 
Therefore, a high level of reporting quality of RCT ab-
stracts is as important as making a huge effort to design 
and conduct researches (6).
Evidence-based dentistry requires clinicians to support 
decisions through clinical evidence. It has been estimat-
ed that more than one hundred periodontology RCTs 
published every year, which are likely to impact clinical 
decision making. In recent years, there were some stud-
ies on the reporting quality of periodontology RCTs. 
In 2016, Leow NM compared the reporting quality of 
periodontology RCTs with the RCTs 14 years ago and 
showed us that the reporting quality had improved but 
not yet optimal (7). Satish Kumar assessed the report-
ing quality of periodontal RCT abstracts published in 
2012 and found that substantial effort is needed to im-
prove the reporting quality (8). Periodontal disease is a 
highly prevalent infectious oral disease. Periodontitis, a 
common periodontal disease, is highly associated with 
systemic consequences, including pulmonary, cardiac, 
and neuronal abnormalities. Therefore, the optimiza-
tion of effective drug therapy for periodontal diseases is 
crucial to prevent systemic diseases. Drug therapy is an 
essential additional method of basic periodontal treat-
ment and surgical treatment. To avoid the abuse of the 
drug and assure rational drug use, clinical drug therapy 
should be based on the current best scientific evidence 
and considered whether to use drug therapy and choose 
the appropriate drug. As RCTs are the highest level 
of evidence, it is imperative to evaluate the reporting 
quality of periodontal RCTs on drug therapy, especially 
their abstracts. As far as we know, this is the first time 
to assess the reporting of RCT abstracts on drug therapy 
of periodontal disease. So the aim of the present study 
was to evaluate the reporting quality of RCT abstracts 
on drug therapy of periodontal disease. In addition, the 
association between reporting quality and some pos-
sible factors has been identified.
Material and Methods 
- Database search strategies
The PubMed database was searched for abstracts of 
periodontal RCTs using the international standard se-
rial numbers (ISSNs) of all dental Science Citation In-
dex (SCI) journals (a total 90), according to the 2018 
Journal of Citation Reports (JCR). The search was 
limited to “humans”, and published in the English lan-
guage during the period of January 1, 2010 to July 17, 
2019. The Medline Subject Heading (MeSH) terms 
used were “periodont* OR gingiv* NOT *implant” 
NOT prevent*[tiab] (9). The search strategy of RCT was 
“randomized controlled trial [pt] OR controlled clinical 
trial [pt] OR randomized [tiab] OR placebo [tiab] OR 
clinical trials as topic [mesh: noexp] OR randomly [tiab] 
OR trial [ti]”, as defined by the “Cochrane Handbook 
for Systematic Reviews for Interventions”. The retrieval 
was done on 2019-07-17.
- Inclusion criteria 
RCTs on drug therapy of periodontal disease were se-
lected. The research reports based on laboratory trials 
using extracted teeth and other types, such as obser-
vational studies, cross-sectional studies, retrospective 
studies, case-controlled studies, reviews, meta-analy-
sis, comments, and letters, were excluded.
- Study screening
The retrieved studies were entered into NoteEx-
pressV3.2.0.6992. Two investigators (A. X and B. Q) 
independently screened the titles and abstracts of the 
retrieved studies. If an abstract couldn’t be identified 
as an RCT, its eligibility was decided following the re-
trieval and analysis of the full text. Any disagreement 
was discussed with a third investigator (C. Y).
- Data collection
Two investigators (A. X and B. Q) collected data from 
the included studies on general features, including 
category of periodontal diseases, trial outcome, drug 
administration, country and continent of first author, 
e628
Med Oral Patol Oral Cir Bucal. 2020 Sep 1;25 (5):e626-33. Quality assessment of RCT abstracts on therapy of periodontal disease
The items were scored as 0, 1 and 2, corresponding to 
“no description”, “inadequate description” and “adequate 
description,” respectively. A score of 2 was considered 
as 100% for each variable. The overall CONSORT score 
(OCS) of each trial was counted including the scores of 
the 19 modified items. Hence, the maximum score that 
could be awarded to a trial was 38. In order to make the 
comparision to the previous studies easier, OCS% was 
calculated (OCS/38). All data were collected using Mi-
crosoft Excel 2007 (Microsoft Corp). Any disagreement 
was discussed with a third investigator (C. Y).
- Data Assessment
Data were statistically analyzed using the SPSS soft-
ware (ver.23.0; IBM SPSS, USA). The mean percentage 
and 95% CI for each item and overall reporting quality 
of each RCT abstract were calculated by descriptive sta-
tistics. In addition, univariate regression analysis was 
conducted to evaluate the possible association between 
reporting quality and potential factors. Then the signifi-
cant factors (P<0.05) were entered in multivariate re-
gression for further analysis. For all analysis, a P-value 
<0.05 was considered statistically significant.
number of authors in the study, journal position in the 
JCR ranking, structured format, word count, inter-
national collaboration, CONSORT endorsement. The 
home page of CONSORT was searched to collect the 
information of journal CONSORT endorsement on 
2019-8-10.
The reporting quality of abstracts of the included stud-
ies was assessed with a modified CONSORT check-
list by two investigators (A. X and B. Q). The original 
CONSORT checklist for reporting RCT abstracts was 
designed for both journal abstracts and conference ab-
stracts, having a total of 17 items with description (2). 
The present study excluded two variables, “Authors” 
and “Recruitment,” which were usually specific for 
conference abstracts. The CONSORT checklist was 
modified with the addition of PICO (Participants, In-
tervention, Comparator and Outcome) evaluation of the 
title, structured format and intention-to-treat analysis 
or per-protocol analysis, and with outcome in results 
break into effect estimates, confidence intervals (CI), 
and reporting of P-values. The final modified checklist 
included 19 items (Table 1).
Item Description
General items
1.Title (PICO) 1. Identifying the study as randomized
2. PICO format
2. Structured Structured format with subtitles (Introduction, Methods, Results, and Conclusion)
3. Trial design Description of trial design (such as parallel, crossover, and non-inferiority)
4. Registration Name of the trial register and registration number 
5. Funding Funding source
Trial methodology
6. Participants Eligibility criteria for participants and settings 
7. Interventions Essential features of interventions intended for each group
8. Objective Specific objective/hypothesis
9. Outcome Explicitly state of the primary outcome for the trial and when it was assessed (e.g. the 
time frame over which it was measured)
10. Randomization Clearly describes the methods for randomization or sequence generation and allocations 
concealment
11. Blinding Report blinding and exactly who was blinded to the group assignment
Trial results
12. Numbers randomized Overall randomized number of participants and number of participants randomized to 
each group
13. Numbers analyzed Overall number of participants and participants analyzed in each group
14. Effect estimate For the primary outcome, a result for each group and the estimated effect size
15. Confidence intervals (CI) Present CI for the contrast among groups
16. Intention-to-treat/per 
protocol analysis
Analyzes everyone who is randomized in the trial, regardless of whether he or she is 
dosed or completes the trial. Or participants who complete the entire clinical trial
17. P-value Reports the P-value
18. Harms Describes the important adverse events/side effects, and if no adverse event has oc-
curred, states this explicitly
Trial conclusions 
19. Conclusions Generally interpret the results and balance the benefits and harms
Table 1: The modified checklist used for the evaluation of RCT abstracts (n=249).
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Results
- Results of literature selection and overall CONSORT 
score (OQS)
As shown in Fig. 1, a total of 1715 articles were retrieved, 
and 249 articles that fulfilled the inclusion criteria were 
finally included for further analysis. The mean OQS of 
all 249 RCT abstracts was 15.6 ± 3.4, which represents 
40.9 ± 0.6% compliance with the checklist.
- Reporting of general items
The scoring results of all 19 items are presented in 
Table 2. The titles of 156 (62.7%) abstracts could be 
identified as randomized and followed the PICO for-
mat. In totally 94.0% of the included abstracts were 
structured, and 88.0% of them were adequately struc-
tured. There were 70 (28.1%) abstracts described the 
exact trial design.
Fig. 1: Flowchart of literature research.
Item No (%) Inadequate (%) Adequate (%)
General items
1.Title (PICO) 35.3 2.0 62.7
2. Structured 6.0 6.0 88.0
3. Trial design 71.9 0 28.1
4. Registration 94.4 0 5.6
5. Funding 100.0 0 0
Trial methodology
6. Participants 3.6 94.8 1.6
7. Interventions 0 59.4 40.6
8. Objective 0.8 0 99.2
9. Outcome 69.1 14.0 16.9
10. Randomization 33.3 66.3 0.4
11. Blinding 59.0 33.3 7.6
Trial results
12.Numbers randomized 6.8 68.3 24.9
13. Numbers analyzed 91.2 6.8 2.0
14. Effect estimate 0 28.1 71.9
15. Confidence intervals 96.0 0 4.0
16. Intention-to-treat/per 
protocol analysis 88.8 11.2 0
17. P-value 34.5 45.0 20.5
18. Harms 83.9 1.2 14.9
Trial conclusions
19. Conclusions 5.2 52.2 42.6
Table 2: Percentage distribution of scoring for items in the modified CONSORT checklist 
for abstracts (n=249).
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Merely 14 (5.6%) abstracts reported trial registration 
and none of the 249 RCT abstracts reported the funding 
sources.
- Reporting of trial methodology
There were 240 abstracts (96.4%) that provided the eligi-
bility criteria for the trial participants, merely 4 abstracts 
(1.6%) reported the settings where the participants were 
investigated. All of the abstracts had the intervention de-
scription, but just 40.6% of them were reported adequate-
ly. The majority of abstracts sufficiently described the ob-
jectives (99.2%). Just 42 abstracts (16.9%) clearly stated 
the primary outcome. Only one abstract (0.4%) explained 
how the sequence generation and allocation concealment 
were reached. Furthermore, 102 abstracts (40.9%) men-
tioned blinding, but merely 19 abstracts (7.6%) accurately 
described who was blinded.
- Reporting of trial results
The majority of abstracts (93.2%) mentioned the total 
number of people participated in the trial, only 24.9% 
of them stated the number of participants randomized 
to each study group. In addition, 8.8% of abstracts men-
tioned about the number of participants analyzed, while 
merely 2.0% of abstracts described further details about 
the number of participants included in each experimen-
tal group. All of the abstracts described the effect es-
timate, and 71.9% of them were adequately reported. 
Most of the abstracts (96%) failed to report the confi-
dence intervals. There were 60.5% abstracts mentioned 
about the P-value, and 20.5% of them reported the ex-
act P-value. Not any of the abstracts clearly described 
the adoption of intention-to-treat analysis/per-protocol 
analysis. In addition, 37 abstracts (14.9%) adequately 
described adverse events.
- Reporting of trial conclusions
A total of 236 abstracts (94.8%) stated the conclusions 
in accordance with results. Among these abstracts, 106 
abstracts (42.6%) balanced the benefits and harms.
- Analysis of associated factors with reporting quality
The results of the linear regression analysis are present-
ed in Table 3.
Independent 
variable Category/unit
Univariate analysis Multivariate analysis
B 95%CI P value B 95%CI P value VIF
Type of 
diseases
Gingivitis Baseline Baseline 
Periodontitis -1.792 (-2.673, -0.911) <0.001 -1.569 (-2.383, -0.755) <0.001 1.06
Outcome
Negative Baseline — — — —
Positive -0.144 (-1.163, 0.876) 0.872 — — — —
Unclear -0.757 (-2.717, 1.202) 0.447 — — — —
Drug 
administration
Local Baseline — — — —
Systemic 0.057 (-0.822, 0.936) 0.899 — — — —
Word count Word 0.021 (0.012, 0.030) <0.001 0.02 (0.012, 0.028) <0.001 1.025
Number of 
authors Author 0.226 (0.030, 0.422) 0.024 0.196 (0.019, 0.374) 0.03 1.06
Continent
Asia Baseline Baseline 
Americas 0.895 (-0.055, 1.845) 0.065 — — — —
Europe 1.74 (0.854, 2.626) <0.001 1.226 (0.420, 2.032) 0.003 1.033
Others (Africa 








Up 0.03 (-0.832, 0.891) 0.946 — — — —
Structured 
format
No Baseline Baseline 
Yes 2.86 (1.130, 4.589) 0.001 2.817 (1.266, 4.368) <0.001 1.021
International 
collaboration
No Baseline Baseline 
Yes 2.27 (1.123, 3.416) <0.001 1.275 (0.179, 2.370) 0.023 1.139
For multivariable analysis, constant=7.488, R2=0.260, adjusted R2=0.242, P=0.000, Baseline: Baseline Reference.
Table 3: Linear regression analysis (univariate and multivariate) coefficients (B) and confidence intervals (95% CI) for quality evaluation, with 
the overall CONSORT score as the dependent variable (n=249).
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According to the univariate analysis, abstracts that 
were about the gingivitis (P<0.001), had structured 
formats (P=0.001), higher word count (P<0.001) and 
more number of authors (P=0.024), had a first author 
that belonged to the European continent (P<0.001), and 
had international collaboration (P<0.001) were a signif-
icantly associated with the greater overall CONSORT 
score (Table 3). In the contrary, no significant differ-
ences were observed for factors as drug administra-
tion, CONSORT endorsement, journal position in JCR 
ranking, which were weeded out from the model. The 
final model included six predictors (P=0.000; R2=0.260 
adjusted R2=0.242). Among these, type of periodontal 
diseases (B=-1.569; P<0.001), word count (B=0.020; 
P<0.001), number of authors (B=0.196; P=0.030), the 
first author from Europe (B=1.226; P=0.003), structured 
format (B=2.817; P<0.001) and had international collab-
oration (B=1.275; P=0.023) still persisted as a noticeable 
predictor of the overall CONSORT score.
Discussion
The results of this study showed that the quality of re-
porting in RCTs abstracts on drug therapy of periodon-
tal disease was suboptimal. The inadequate reporting of 
abstracts was in line with previous studies on dentistry 
(10-12), as well as on other specialties (13-15). These re-
sults manifested a lack of adherence to the CONSORT 
guidelines for RCT abstracts.
In terms of title, the deficient reporting of randomiza-
tion may lead to irrelevant to database retrieval and 
omissions, leading to biases in systematic reviews. In 
the present study, 64.7% of abstracts titles could be 
identified as randomized, which was remarkably bet-
ter than those of previous studies (13,16). In contrast, 
13.2% of abstracts contained no information about 
“random”, neither in the title nor in the body of the ab-
stract. Investigators could only identify these studies as 
RCTs after carefully reading their full texts. It is worth 
to mention that the full text could not always be easily 
accessed, which may lead to indexing omission by read-
ers. In addition to mentioning “random”, the title can be 
improved following the PICO format (10). Surprisingly, 
merely 15.5% of abstracts in the present study ideally 
followed the PICO format.
Blinding is a very important method to reduce or even 
avoid bias from therapists, assessors or patients (2). 
The intervention design of drug therapy in periodon-
tal RCTs can be absolutely designed as blinding. For 
example, tablets used in an RCT can be made to have 
virtually the same appearance, so that people can’t 
identify the experimental tablets from the control ones. 
But in our study, blinding was found to be inadequately 
reported. Less than half of the abstracts reported blind-
ing, and a very few of them accurately reported who 
was blinded. This may result in difficulty for readers in 
assessing the methodological quality of RCTs through 
their abstracts that have not expressed blinding effec-
tively and precisely. Additionally, bias interpretations 
or overestimates may be induced. A study showed that 
non-blinded patients might exaggerate the effect size by 
0.56 standard deviation (17). Another study proved that 
non-blinded assessors might overestimate the effect in 
the treatment groups and underestimate the effect in the 
control groups (18).
In this study, we modified outcomes in results into three 
items, including effect estimate, confidence intervals, 
and P-value, according to a previous study published 
in 2013 (11). In this way, we got more details about out-
comes in results. Effect estimate was well reported by a 
large proportion of included abstracts. But the reporting 
quality of confidence intervals and P-value were not so 
good, especially confidence intervals. These two items 
can reflect the statistical significance of observed treat-
ment effects of a trial. The value of a trial in treatment 
decision making is whether its treatment effect can be 
trusted on or not (19). Poor reporting quality of confi-
dence intervals and P-value may make it difficult for 
readers to assess the trial effect accurately and compre-
hensively. More than half of the abstracts in our study 
mentioned P-value, but only 20.5% of them reported the 
exact P-value. A study proved that approximate P-value 
may lead to less reliable conclusions compared to the 
exact P-value (20).
The CONSORT guidelines for RCT abstracts suggested 
reporting the funding source, especially in drug re-
searches. It is strange to find that none of the included 
RCT abstracts reported “funding”. It may influence 
the interpretation of the trial results by readers (21). A 
study revealed that studies funded by pharmaceutical 
companies might selectively report outcomes that are 
more favorable to the funder when compared to re-
searches funded by neutral sources, thereby leading to 
the possibility of publication bias (22). Another study 
also proved that the results and conclusions might more 
favorable for the sponsor’s drugs than the comparator 
ones in drug-drug comparison trials (23). So readers 
should be careful when reading drug RCTs to assist in 
their choice for drug use in clinical treatment.
We also found that six factors had a statistically signifi-
cant association with reporting quality of RCT abstracts 
in linear regression analysis. Among them, two factors 
(structured format, word count) had been reported as 
statistically significant in the previous studies (3,12,24). 
It is interesting to find that abstracts on drug therapy 
of gingivitis were better reported than periodontitis. 
We also found that the vast majority of the drugs used 
for gingivitis therapy were contained in dentifrice or 
mouthwash for home dental care. So the reason for 
worse reporting quality in periodontitis may be that 
the form of drug use in periodontitis is relatively more 
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diverse and make reporting quality unevenness. RCTs 
had more number of authors and international collabo-
rations were associated with better reporting quality in 
abstracts. A study also found that the “number of au-
thors” involved in conducting an RCT is directly associ-
ated with the reporting quality of the abstract (25). This 
may be because the authors had their own research and 
article submission experience. Different experiences 
may increase the possibility of endorsing and following 
the CONSORT guideline. Authors from different coun-
tries may also increase the chance to realize and follow 
the guidelines. Abstracts of studies conducted by Eu-
ropean authors were better reported than authors from 
other continents. These findings are consistent with pre-
vious studies (8,10,12), and indicated that CONSORT 
guidelines were better followed by European authors.
It is delighting that an increasing number of journals 
stated their endorsement of the CONSORT statement 
in their guidelines for authors. Contrary to our expec-
tations, although 71.9% of articles from CONSORT-
endorsing journals, the reporting quality had no sig-
nificant difference when compared to articles from 
non-endorser journals. This finding is consistent with a 
previous study (8). One reason for this may be the low 
endorsement of the CONSORT guideline for abstracts. 
A study in 2016 found that the endorsement of the 
CONSORT guideline for abstracts was only 7% (26). 
Another reason may be the low execution of the edi-
tors and publishers and poor compliance of authors. In 
consideration of the importance of RCT abstracts, as we 
discussed before, journals should improve the endorse-
ment rate of CONSORT guidelines for abstracts. Edi-
tors and publishers should place more emphasis on the 
reporting quality of abstracts, and encourage authors to 
strictly adhere to the guidelines since these are espe-
cially critical in making the accelerating improvement 
directly.
Our study has some limitations. Firstly, our study didn’t 
present all the RCTs in periodontology, so our results 
may not be generalizable to all the RCTs in periodontol-
ogy. However, drug therapy is very normal in daily clin-
ical practice in the periodontal department and has its 
own features as we discussed above, so assessing their 
reporting quality is meaningful for clinical research-
ers and guideline makers. Secondly, we searched only 
SCI journals, some RCTs on this topic may be missed 
from the current research. But SCI journals are more 
representative than other journals. The present study 
has certain strengths. Firstly, it is the first time that fo-
cused on the reporting quality of drug therapy in peri-
odontal diseases. The study comprehensively searched 
abstracts of 249 periodontal RCTs in 90 dental SCI 
journals, according to the 2018 Journal Citation Report, 
which differed from the previous studies, which only 
included several top journals in the specialty (3,10,12). 
The present study strictly complied with the CONSORT 
statement for abstracts checklist, and carefully studied 
its explanation in facilitating the assessment. And we 
added “inadequate description” and “adequate descrip-
tion” to score the items, and extracted more details from 
the included abstracts. We also summarized a check-
list for the explanation of “inadequate description” and 
“adequate description”. A study in 2018 assessed the 
reporting quality of periodontal disease RCT abstracts 
(8), and the study just used “reported” or “no report-
ed” to score the items. For some items, this method is 
enough just as funding, registration, confidence inter-
vals. But for some items contain a lot of information, 
just like randomization, participants, interventions, this 
simple way may not be enough to assess the RCTs in a 
more elaborate way. For example, the vast majority of 
the included RCT abstracts described participants, but a 
few of them contained the information about where the 
data was collected, which was also important for this 
item. More details can lead us to further, and deeper 
analyze the reporting quality. Undoubtedly, this modi-
fied CONSORT guideline needs further study for gen-
eral applicability.
Conclusions
The reporting quality of drug therapy RCTs in peri-
odontal disease in SCI journals was suboptimal. Clini-
cal workers and clinical guideline makers should care-
fully in selecting and adopting the information in drug 
therapy RCTs in periodontal disease. It is not enough 
just to endorse the CONSORT guidelines, strictly fol-
lowing the guidelines to report RCT abstracts is the 
place where more efforts should be made.
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